陽普醫療(300030.SZ)2019年度預盈2500萬-3000萬元 同比扭虧為盈
格隆匯2月2日丨陽普醫療(300030.SZ)公佈,預計2019年度歸屬於上市公司股東的淨利潤2500萬元-3000萬元,上年度虧損1.37億元。公司2019年年度業績變動的主要原因如下:
1、報告期與去年同期相比實現扭虧為盈,主要是因為2018年公司子公司未能達成業績原有預期,計提了大額商譽減值,導致去年同期虧損。報告期,公司聚焦主營產品的推廣和銷售,主營業務穩定增長,銷售收入比去年同期增長5.69%。
2、報告期,公司參股子公司深圳市陽和生物醫藥產業投資有限公司發展勢頭良好,公司預計對該子公司計提歸屬於上市公司股東的投資收益1100萬元。
3、報告期,公司非經常性損益對歸屬於上市公司股東淨利潤的影響額約1050萬元;去年同期,非經常性損益對歸屬於上市公司股東淨利潤的影響額1020.41萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.